AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04640883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inclusion of sprints during low-intensity cycling during a 14-day training camp (high training load)
Description: Inclusion of 12x30-s maximal sprints during five low-intensity cycling sessions with long duration (>fours hours per session). Five sessions will be performed as low-intensity cycling-only (Controll sessions, distance matched). All other sessions will be performed as low-intensity sessions and adjusted according to each participants training load goal to reach an increase of \~50% in load compared to habitual training.
Study NCT04640883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity cycling during a 14-day training camp (high training load)
Description: Five low-intensity cycling sessions (>four hours per session), distance-matched to sprint group.
Study NCT04640883 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recovery for 10 days (low training load)
Description: Habitual low-intensity cycling (>0.5-2 hours per session)
Study NCT04640883 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recovery for 10 days (low training load)
Description: Habitual low-intensity cycling (>0.5-2 hours per session)
Study NCT03764852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient laparoscopic
Description: The intervention is a outpatient laparoscopic sacrocolpopexy with robotic assistance.
Study NCT03764852 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: outpatient laparoscopic
Description: The intervention is a outpatient laparoscopic sacrocolpopexy without robotic assistance.
Study NCT00540189 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Initial appendectomy
Study NCT00540189 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Interval appendectomy
Study NCT01926483 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neoadjuvant Chemoradiotherapy
Description: Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
Study NCT03442543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: preoperative localization of SLN detected by CTLG by either methods
Description: 50 patients with node negative early breast cancer. The patients were randomized into two groups; SLN localized using CTLG guided injection of liquid charcoal suspended solution (first group) or by placing a 3 cm silver wire using spinal needle (second group). For every patient, SLN biopsy was performed using the traditional method with blue dye. Then dual search for the SLN localized by both the novel \& traditional method was performed.
Study NCT03884582 — intervention group
Intervention type: DEVICE
Intervention: Cova Monitoring System 3
Description: Healthy Volunteers
Study NCT01727609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk feed (breast milk or formula milk)
Study NCT01727609 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Milk feed (breast milk or formula milk)
Study NCT02326415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Pathway with Fast-Track
Description: Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
Study NCT02326415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative Usual Protocol
Description: Cares step by step as sugery responsable thinks are the best for patients until discharge.
Study NCT03840655 — intervention group
Intervention type: PROCEDURE
Intervention: Near-Infrared Imaging Thoracoscopy
Description: Sympathicotomy performed by near-infrared imaging thoracoscopy
Study NCT04304027 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored exercise intervention
Description: 2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at target heart rate reserve followed by 2 minutes working rest (target heart rate reserve may vary between sessions depending on the level of self-reported fatigue)
Study NCT04304027 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise intervention
Description: 2x 30 minute aerobic interval training per week for 8 weeks - sessions involve 6 intervals cycling for 2 minutes at >70% heart rate reserve followed by 2 minutes working rest
Study NCT05113836 — intervention group
Intervention type: BIOLOGICAL
Intervention: Deep nasopharyngeal swab
Description: On admission in ICU, a deep nasopharyngeal swab will be performed (15mL).
Study NCT05113836 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sample at D1, D3 and D7
Description: Specific samples for research and lipid analysis will be performed at D1, D3 and D7:~Assessments will be carried out on the same blood tube as the blood ionogram carried out as part of the usual management.~This means a 5 ml tube of blood on EDTA medium will be taken at the same time as the blood ionogram for the treatment at D1, D3 and D7 (15mL in total).
Study NCT02167932 — intervention group
Intervention type: BEHAVIORAL
Intervention: Walk With Ease
Description: Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
Study NCT03524261 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Activated CIK and CD3-MUC1 Bispecific Antibody in Treating Breast Cancer
Description: CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
Study NCT03524261 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT03524261 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy
Description: the maximum tumor length≥2 cm，cool down the lesion,result in degeneration, necrosis or loss of the lesion.
Study NCT02833103 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danshu Capsules
Description: Danshu Capsules (0.9g potid/day) for three months by oral
Study NCT02833103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinaverium Bromide
Description: Pinaverium Bromide (100mg potid/day) for three months by oral
Study NCT01206205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide, Bortezomib
Description: Induction:~3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14~Consolidation (2 months After ASCT):~2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14~Maintenance Phase:~3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months
Study NCT03217838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2811
Description: AZD2811 will be administered by IV infusion with the specified dose level as reported in arms in 28-day cycles.
Study NCT03217838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Azacitidine is supplied in vials of 25 mg/mL powder for suspension for injection. After reconstitution, each vial contains a maximum of 100 mg. Participants should be pre-medicated for nausea and vomiting according to institutional standards before receiving azacitidine. Participants will receive 75 mg/m² on Days 1 through 7 or for 5 consecutive weekdays with rest on the 2 weekend days, and azacitidine dosing the first 2 weekdays of the next week of each 28-day cycle.
Study NCT03217838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax (VENCLEXTA®) is approved by the FDA for use in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly-diagnosed AML in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. Venetoclax is planned to be given at a dose of 100 mg orally (PO) on Day 1 and 200 mg (PO) on Days 2- 28 of each 28-day cycle or 100 mg orally (PO) on Day 1, 200 mg PO on Day 2, and 400 mg PO from Days 3 to 28 of each 28-day cycle. The third participant in Group 3 Arm A will only be enrolled after the first 2 participants will receive ≥2 weeks of treatment and have shown no evidence of toxicity observed to be compatible with a DLT.
Study NCT05779072 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Single Vision Soft Contact Lens
Description: Subjects refit to Single Vision Soft Contact Lens for 1 year
Study NCT00506883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Colchicine (4.8 mg total dose)
Description: At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
Study NCT00506883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose Colchicine (1.8mg total dose)
Description: At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
Study NCT00506883 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
Study NCT02870309 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP
Description: Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
Study NCT03759626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impulsive intervention
Description: As part of the IMAJe project, a 20 min TV series pilot for teenagers was developed by C. Russel of Washington University : Tom in the making. The results of the study show that the mere diffusion of this pilot mobilizes the individual's impulsive system described in the theoretical model developed by Strack and Deutsch. 2 different versions have been developed. Both have the same basic story in three acts with the same main characters. Only the last acts vary according to the consequences of alcohol consumption. The first version shows a positive representation of alcoholization, the other highlights the negative consequences generated by this behaviour. Our tool will be the so-called negative version of the episode where alcohol consumption causes harmful consequences in the young person's life. Following this 20 min episode, a 25 min debate focusing on the characters in the series will be conducted using a questionnaire grid with 8 questions.
Study NCT03759626 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reflective Intervention
Description: This intervention uses modules of the KOTTABOS ® system produced by the National Association for the Prevention of Alcohol and Addiction 59 (ANPAA) and validated by the Interministerial Mission to Combat Drugs and Drug Addiction (MILT). For young people, this educational tool aims to develop an understanding of the mechanisms of blood alcohol levels, the effects and immediate risks associated with alcohol consumption.~It encourages individual and collective reflection on the effects of alcohol on physical, cognitive and intellectual abilities in order to increase individual skills in making risk-appropriate behavioural choices. This pedagogical tool is based on a participatory and experimental approach. 5 devices of the KOTTABOS ® tool were selected and tested with 2 test groups of adolescents of the same school level as the students in the study.
Study NCT00399165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Oral Testosterone 400 mg orally for 28 days
Study NCT00399165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Enanthate
Description: Oral Testosterone 800 mg orally for 28 days
Study NCT00399165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: dutasteride 0.5 mg orally, once daily for 28 days
Study NCT00399165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo sesame oil
Description: placebo sesame oil
Study NCT00399165 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dutasteride
Description: 24.5 mg po once (Day 0)
Study NCT01946607 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citalopram
Study NCT01946607 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02339493 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer Electronic Alert
Description: A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
Study NCT04593654 — intervention group
Intervention type: DRUG
Intervention: Dose of tinzaparin or dalteparin
Description: The patients will be categorised into three groups depending on initial dose of thromboprophylaxis in the ICU
Study NCT00023374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 6mos REZ intermittent
Study NCT00023374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazinamide
Description: 6mos REZ intermittent
Study NCT00023374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethambutol
Description: 6mos REZ intermittent
Study NCT00023374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REZ
Description: Rif+PZA+EMB given 2 or 3 times weekly for 6 months
Study NCT03657251 — intervention group
Intervention type: GENETIC
Intervention: liquid biopsy
Description: Participants will be asked to provide up to a maximum total 40 mL of blood for all of the required sample collection. Peripheral blood will be collected from patients who consent to the protocol. These samples will be obtained at a time scheduled by the participant with the phlebotomy service provider, and will be collected at the participant's home. Patient peripheral blood samples can be obtained at diagnosis or at any time in follow up.
Study NCT01570673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group urotherapy
Description: Children in this arm will receive group urotherapy in small groups with other children.
Study NCT01570673 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Urotherapy
Description: Children will receive standard individual urotherapy in regular pediatric urology clinic.
Study NCT01827033 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: meditation training
Study NCT01353703 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa™
Description: Intramuscular, three doses
Study NCT01353703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa™
Description: Intramuscular, three doses
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted low dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted low dose of quadrivalent VLP vaccine
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted medium dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted medium dose of quadrivalent VLP vaccine
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-adjuvanted high dose of quadrivalent VLP vaccine
Description: A single non-adjuvanted high dose of quadrivalent VLP vaccine
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted low dose of quadrivalent VLP vaccine
Description: A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted high dose of quadrivalent VLP vaccine
Description: A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
Study NCT02236052 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single dose of placebo
Study NCT00096863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Study NCT00096863 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Study NCT00096863 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01787916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liraglutide
Description: Liraglutide will be compared to placebo for 24 weeks in a cross-over design
Study NCT01787916 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: placebo will be compared to liraglutide for 24 weeks in a cross-over design
Study NCT01090882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivocaine
Description: 20ml 0.25% at beginning of operation
Study NCT01090882 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivocaine
Description: 20ml 0.25% at beginning of operation
Study NCT01090882 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 0.9% normal saline solution
Description: 20ml 0.9% NaCl
Study NCT00962832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as a sterile liquid solution.
Study NCT00962832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rontalizumab
Description: Rontalizumab was supplied as a sterile liquid solution.
Study NCT03881397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Media Use Plan
Description: A tool developed by the American Academy of Pediatrics that engages teens and parent to discuss internet safety ideas and develop rules around technology use together.
Study NCT03881397 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Use Resources Awareness
Description: Resources offered to parents and teens that include tools and publicly available resources for safe technology use among teens
Study NCT03664999 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: differences between dynamics of the complement components C1 inhibitor, C1 inhibitor activity, C3, C4 during the labour in a group of women with physiologic pregnancy and in a group with a risk of complications (pre-eclampsia, HELLP syndrome, placenta praevia, placental abruption, IUGR, previous post partum hypotony).
Study NCT03506243 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Follitrope PFS
Description: Follitrope PFS
Study NCT03506243 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gonal-f pen
Description: Gonal-f pen
Study NCT00640328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 100
Description: 100mg
Study NCT00640328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 300
Description: 300mg
Study NCT00640328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab 700
Description: 700mg
Study NCT00640328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placebo
Study NCT02278172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: 3000IU (75 μg) vitamin D in a commercially available oral spray solution
Study NCT02278172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral spray solution manufactured to mimic the vitamin D oral spray
Study NCT04324372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC68498
Description: HEC68498 is a potent,highly selective inhibitor of class 1 isozymes of phosphoinositide 3-kinase/mammalian(PI3K) and of the mammalian target of rapamycin (mTOR). It has shown good activity against fibrosis and inflammation in vitro and in vivo, with a lower effective dose and better efficacy than pirfenidone and nintedanib.
Study NCT01666327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-1303
Study NCT01520571 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Computer Assistance TKA
Description: Non-Computer Assistance Total Knee Arthroplasty
Study NCT01520571 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computer Assistance TKA
Description: Computer Assistance Total Knee Arthroplasty
Study NCT00357500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Study NCT00357500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00357500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide